

Questions about the newsletter? Write to giorgio.barbareschi@eatg.org

What's New?

PROMise: FACE-TO-FACE STAKEHOLDER WORKSHOP

Under the scope of the PROMise project, EATG organised in **Brussels** on the 17th of June an **in-person stakeholder workshop** that brought together **15 representatives** from community, pharmaceutical companies and academia to explore a methodology for discussion and consensus on various aspects of Patient Reported Outcome Measures (PROMs) in HIV R&D. After a background update on EATG's work on the topic, new products in the pipeline and their desirable attributes were explored and regulatory participation was discussed. The objective of this workshop was to agree on a consensus-building methodology and we **"PROMise" something new is up!**

F2F PiS PROGRAMME COMMITTEE MEETING

On the 27th and 28th of June, members from the PiS committee and the EATG staff met in **Brussels** for their annual programme committee meeting. The two-day meeting included **programmatic planning**, such as reviewing the 2022 workplan, **developing the 2023-25 implementation plan**, an interactive session on **project progress and updates** and discussion on **thematic issues** such as viral hepatitis and ageing. We remembered the value of meeting face to face while we came together to brainstorm strategies to overcome key challenges of working as community partners with other stakeholders. We also looked at ways to improve scientific training and information for EATG and other community members... **watch this space!**

RBDCOV PROJECT GENERAL ASSEMBLY

For the long-anticipated **face to face RBDCOV Project General Assembly**, EATG joined partners in **Amer, Spain** at the **HIPRA pharmaceutical facilities** for a site visit and full day project meeting. After 7 months of meeting online only since the project start date, it was very refreshing to finally meet in person and discuss project progress. Six EATG members have been working in close **collaboration with the EATG staff and all the partners** throughout all the working packages and phases of this project, providing valuable input in order to make sure that the **community perspective is included**.

WHAT'S NEXT?

- Organise **two f2f ECAB meetings** (September & October).
- Webinar on the **EHVA T02 trial for a Therapeutic Vaccine** - July 13, 2022.
- Finalise the **advocacy position paper** on the inclusion/exclusion of PLHIV in non-HIV clinical trials.

FOLLOW THE EUPATI OPEN CLASSROOM!

Want to learn more on medicines R&D? The **EUPATI Open Classroom** is a **personalised, flexible and on-demand e-learning platform** designed for patients, patient representatives and other stakeholders. And it is **free for EATG members!** Click on the logo or scan the QR Code to find out more.



PiS WANTS YOU!

Want to join the **ECAB & Protocol Review Pools?**
Click here to apply!



SAVE THE DATE: EVENTS & CONFERENCES



- **24th International AIDS Conference (AIDS 2022):** 29 July - 2 August 2022, Montreal, Canada and online.
- **ECAB with Gilead Sciences:** 09 - 10 September 2022, Frankfurt am Main, Germany.
- **IAPAC Fast-Track Cities Conference:** 11-13 October 2022, Sevilla, Spain and online.
- **HIV Glasgow 2022:** 23 - 26 October 2022, Glasgow and hybrid.
- **STEPS Cure VIII - Webinar:** 23 October (TBC).

Meet the PiS Member: Brian West

Who is Brian West in a nutshell?

I am a gay man who has been living with HIV since 1983 - nearly 39 years now! I live in Edinburgh, Scotland and I have a PGD in Social Development and Health from Queen Margaret University and a long standing history in involvement in HIV/AIDS activism. I was involved with Waverley Care from 1996 onwards - originally as a service user, then serving on the Trustees Board for over 10 years. I previously sat on the Board of Directors of HIV Scotland and I have given community submissions into the Scottish Medicines Consortium. I am also a member of the UKCAB. I came to the EATG through ECAB - as HIV science has always interested me.

What is that you like most about PiS and what is from your perspective one of the main achievements of the programme?

The thing I like most about PiS is the fact that it focuses on science: I believe in equal access to HIV treatments for all and new treatments and novel treatment strategies are as important now as ever. I was happy to become Chair of PiS and hopefully give some of the experience I have learnt through the EATG into the Programme. I understand the history of the EATG well - good times and bad! I think the main achievements of PiS are keeping the community's interests at the heart of treatment and making sure our voices are heard.



EATG member since **2008**, Brian has served **6 years** on the **EATG Board of Directors**. He is currently the **Chair of PiS** and serves on the **Board of the European Patients Forum** on behalf of the EATG.